Acute Ischemic Stroke Clinical Trial
Official title:
Research on the Association of Gut Microbes and Their Metabolites With Post-stroke Depression
NCT number | NCT05414227 |
Other study ID # | XYFY2022-KL204 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 6, 2022 |
Est. completion date | May 31, 2023 |
In this study, the clinical data of patients with AIS were collected, 16s RNA was used to detect the composition and diversity of intestinal flora, and flow cytometry and mass spectrometry were used to detect intestinal flora-related metabolites in plasma,to explore the influence of gut microbiota and its metabolites on stroke prognosis.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | May 31, 2023 |
Est. primary completion date | February 28, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients who suffered from acute ischemic stroke 2. Within 7 days of the onset 3. Signing the informed consent, willing and able to attend all study visits Exclusion Criteria: 1. Severe aphasia,dysarthria, hearing loss,cognitive and consciousness impairment and unable to cooperate 2. Previous diagnosis of depression or other mental disorder or who had recently accepted antidepressants or antipsychotics 3. Gastrointestinal disease, and pregnant or lactating women 4. Serious systemic diseases including malignant tumors 5. Any antibiotics, probiotics or prebiotic treatment within 1 months |
Country | Name | City | State |
---|---|---|---|
China | The Affiliated Hospital of Xuzhou Medical University | Xuzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The Affiliated Hospital of Xuzhou Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The PSD Assessed by Hamilton Rating Scale for Depression (HAMD-17) Score | Mild depression(HAMD-17 Score=7,<17), moderate depression(HAMD-17 Score=17,<24), major depression(HAMD-17 Score=24) | 3 months | |
Primary | The PSD Assessed by Hamilton Rating Scale for Depression (HAMD-17) Score | Mild depression(HAMD-17 Score=7,<17), moderate depression(HAMD-17 Score=17,<24), major depression(HAMD-17 Score=24) | 6 months | |
Primary | The PSF Assessed by Fatigue Severity Scale(FSS) | Fatigue(=36) | 3 months | |
Primary | The PSF Assessed by Fatigue Severity Scale(FSS) | Fatigue(FSS Score =36) | 6 months | |
Primary | Functional Independence Assessed by Modified Rankin Scale (mRS)score | MRS score range from 0 to 6. Favourable outcome (mRS score=2), worse outcome (mRS score>2), and death (mRS score = 6) | 3 months | |
Primary | Functional Independence Assessed by Modified Rankin Scale (mRS)score | MRS score range from 0 to 6. Favourable outcome (mRS score=2), worse outcome (mRS score>2), and death (mRS score = 6) | 6 months | |
Secondary | Gut microbial composition and diversity | Results of fecal bacteria by 16s RNA sequencing | First stool after admission | |
Secondary | Serum metabolites of gut microbiota | Serum metabolites of gut microbiota from stool, detected by liquid chromatography-mass spectrometry (LC-MS) combined technique | 7 days within stroke onset | |
Secondary | Serum inflammatory cytokines | Inflammatory cytokines in blood,detected by flow cytometry | 7 days within stroke onset |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |